The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•7 May 2026•

1 min read

Xeris Biopharma Swings to Profit in Q1 2026 as Recorlev Sales Double

Key Facts

1Xeris Biopharma reported a net income of $2.2 million in Q1 2026, compared to a $9.2 million net loss in the prior year.

2Total revenue increased by 38.3% to $83.1 million, largely driven by Recorlev net product revenue nearly doubling to $49.8 million.

Xeris Biopharma (XERS) reported a significant financial turnaround in the first quarter of 2026, posting a net income of $2.2 million compared to a $9.2 million loss in the prior year. The company's total revenue surged by 38.3% to reach $83.1 million, primarily fueled by a near 100% increase in net product revenue from Recorlev, which totaled $49.8 million. Xeris also demonstrated operational strength by generating $9.9 million in operating cash flow during the period. Despite these gains, the firm continues to manage a substantial long-term debt load of $221.2 million and ongoing patent infringement litigation. This shift to profitability marks a critical milestone for the mid-cap biotech firm, offsetting higher research and development costs. Investors are closely watching the sustainability of this growth as the company navigates its legal and financial obligations.